论文部分内容阅读
目的观察帕罗西汀早期联合氟哌噻吨美利曲辛治疗脑卒中后抑郁(PSD)的疗效。方法将PSD患者125例随机分为研究组63例和对照组62例。对照组给予药帕罗西汀治疗,研究组给予药帕罗西汀联合氟哌噻吨美利曲辛治疗,对比2组治疗前、治疗14d及28d后Hamilton抑郁量表(HAMD)评分及神经功能缺损程度评分(NIHSS),对比2组患者的临床疗效。结果治疗14d及28d后2组HAMD评分及NIHSS评分均显著降低,且研究组低于对照组,差异均具有统计学意义(P<0.05)。研究组总有效率为98.41%高于对照组的87.10%,差异有统计学意义(P<0.05)。结论帕罗西汀早期联合氟哌噻吨美利曲辛治疗PSD患者疗效显著,可有效改善患者的情感障碍,恢复机体神经功能,值得临床推广应用。
Objective To observe the efficacy of paroxetine combined with flupenthixol and melitrace in the treatment of post-stroke depression (PSD). Methods 125 patients with PSD were randomly divided into study group 63 cases and control group 62 cases. The control group was treated with paroxetine. The study group was treated with paroxetine and flupentixol and melitracen. The scores of Hamilton Depression Rating Scale (HAMD) and neurological deficit score before treatment, 14 days and 28 days after treatment were compared between two groups (NIHSS), comparing the clinical efficacy of two groups of patients. Results The HAMD score and NIHSS score of two groups were significantly decreased after treatment 14d and 28d, and the study group was lower than the control group, the difference was statistically significant (P <0.05). The total effective rate was 98.41% in the study group and 87.10% in the control group, with significant difference (P <0.05). Conclusion Paroxetine combined with flupentixol and melitracen in the treatment of PSD patients has significant curative effect, which can effectively improve the patients’ affective disorder and restore the nerve function of the body, which is worthy of clinical application.